August 4th, 2014
Selections from Richard Lehman’s Literature Review: August 4th
Richard Lehman, BM, BCh, MRCGP
CardioExchange is pleased to reprint this selection from Dr. Richard Lehman’s weekly journal review blog at BMJ.com. Selected summaries are relevant to our audience, but we encourage members to engage with the entire blog.
JAMA Intern Med August 2014
Trends in Use of Ezetimibe After the ENHANCE Trial (OL): Once more it is time to praise Joe Ross. He has two articles waiting to see print in JAMA Internal. The first one tracks the continuing use of ezetimibe in the United States following the ENHANCE trial, which demonstrated that ezetimibe use lowered cholesterol levels, but did not slow the progression of atherosclerosis. He and his team looked at the records of 10 597 296 continuously eligible adults in the USA, and found that nearly three years after ezetimibe had been shown to do nothing, 186 272 of them were still ezetimibe users, i.e. 1.8% of the total adult population.
NEJM Journal Watch — Recent Cardiology Articles- Persistent Symptoms After Valve Replacement for Severe Aortic Stenosis
- Is Diltiazem Safe in Patients with AF Taking Apixaban or Rivaroxaban?
- Does Lowering High Childhood Lipid Levels Prevent Adverse Cardiovascular Events in Adulthood?
- Self-Expanding Supraannular Valve vs. Balloon-Expandable Valve in TAVR for Small Aortic Annulus
- A New TAVR Prosthesis for Aortic Regurgitation Shows Promise